BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19509138)

  • 21. [Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
    Asano T; Namikawa O; Yamamoto A; Sano T; Mukai J; Kawaji K; Kobayashi M
    Nihon Kokyuki Gakkai Zasshi; 1998 Sep; 36(9):771-5. PubMed ID: 9866979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
    Sugiyama T; Nishida T; Kataoka A; Imaishi K; Komai K; Ushijima K; Hasuo Y; Ookura N; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Sep; 48(9):827-34. PubMed ID: 8841050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.
    Natsume T; Watanabe J; Koh Y; Fujio N; Ohe Y; Horiuchi T; Saijo N; Nishio K; Kobayashi M
    Cancer Sci; 2003 Sep; 94(9):826-33. PubMed ID: 12967483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
    Osaki S; Nakanishi Y; Takayama K; Pei XH; Ueno H; Hara N
    Cancer Gene Ther; 2000 Feb; 7(2):300-7. PubMed ID: 10770640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
    Matsumura Y
    Adv Drug Deliv Rev; 2011 Mar; 63(3):184-92. PubMed ID: 20561951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts].
    Miki T; Kotake T
    Hinyokika Kiyo; 1993 Dec; 39(12):1221-5. PubMed ID: 8285173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines.
    Kondo H; Kanzawa F; Nishio K; Saito S; Saijo N
    Jpn J Cancer Res; 1994 Oct; 85(10):1050-6. PubMed ID: 7961107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
    Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
    J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
    Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
    Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
    Isobe T; Onn A; Morgensztern D; Jacoby JJ; Wu W; Shintani T; Itasaka S; Shibuya K; Koo PJ; O'Reilly MS; Herbst RS
    J Thorac Oncol; 2013 Feb; 8(2):140-6. PubMed ID: 23328546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer.
    Yanagihara K; Takigahira M; Kubo T; Ochiya T; Hamaguchi T; Matsumura Y
    Ther Deliv; 2014 Feb; 5(2):129-38. PubMed ID: 24483192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of a new anti-cancer drug regimen for surface epithelial-stromal ovarian cancer].
    Fushiki H; Hidaka T; Hori S; Fujimura M; Yamakawa Y; Izumi R
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):731-4. PubMed ID: 9571971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
    Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
    Kumazawa E; Jimbo T; Ochi Y; Tohgo A
    Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
    Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH
    Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth.
    Cheng YS; Peng YB; Yao M; Teng JP; Ni D; Zhu ZJ; Zhuang BF; Yang ZY
    Biochem Biophys Res Commun; 2017 Jun; 487(3):567-572. PubMed ID: 28431928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
    Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.